Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
PHASE4
The purpose of this study is to determine whether the rituximab administrat...
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
PHASE1
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T...
Status
Not Yet Recruiting
Location
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
PHASE1
This is a Phase 1 study evaluating the safety of ABT-263 administered in co...